Market Overview

Pacific Crest Downgrades VeriFone, Concerned Emerging Market Woes Have Worsened

Share:

Pacific Crest's Josh Beck downgraded VeriFone Systems Inc (NYSE: PAY) to Sector Weight with a price target between $22 and $24. The rating change came after VeriFone reported earnings and guidance short of analyst estimates.

Petro remained strong, surprising revenue estimates, but margins and international sales disappointed. "Media weakness and the EMV bottleneck pressured services revenue and margins while a mix shift between multi-lane/ SMB and petro weighed on product gross margin," according to Beck.

Additionally, the analyst believed new restructuring plans will "mitigate revenue and gross-margin pressures," but overall gross-margins will decline in 2016 with a slight rebound in 2017.

At time of writing, VeriFone traded at $21.26, down 24.69 percent on the day.

Latest Ratings for PAY

DateFirmActionFromTo
Apr 2018DowngradesBuyHold
Apr 2018DowngradesBuyHold
Apr 2018MaintainsNeutralNeutral

View More Analyst Ratings for PAY
View the Latest Analyst Ratings

Posted-In: Josh Beck Pacific CrestAnalyst Color Downgrades Price Target Analyst Ratings

 

Related Articles (PAY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
NKEGuggenheimMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Celebrity-Endorsed Junk Food: What's The Cost?

Here's Why You Should Watch For Movement In Lipocine Tomorrow